A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 757 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole... August 11, 2021 Community Comes Together To Give Terminally Ill Father One Last Christmas... October 18, 2021 FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... July 24, 2024 People with Intellectual Disability at Increased Risk of Cancer September 21, 2021 Load more HOT NEWS Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, and PIVOT-09 ΥΓΡΗ ΒΙΟΨΙΑ: ΤΟ ΜΕΛΛΟΝ ΣΤΗ ΔΙΑΓΝΩΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma Free Rides to Screening Appointments Thanks to Woman Who Lost Mother...
